Summary Allelic losses on the short arm of chromosome 17 occur frequently in colorectal cancers. Despite the existence of other common molecular events such as loss of the long arms of chromosomes 18 and 5, it has been demonstrated that the former has the greatest prognostic significance. Of the various genes mapping to the commonly deleted sequence, the best candidate as a 'target' seems to be the p53 antioncogene. We applied our An increasing body of evidence implicates the cellular antioncogene p53 in the development of human colorectal malignancy. In parallel to the discovery of the recurrent loss of the short arm of chromosome 17 (17p) by cytogenetic analysis (Muleris et al., 1985; , allelic losses were described, with probes specific for the short arm of chromosome 17, as well as for other chromosome segments (Fearon et al., 1987; Law et al., 1988; Delattre et al., 1989; Vogelstein et al., 1989; Fearon et al., 1990) . The deletions on 17p were found to encompass a common region containing the p53 gene ) and mutations have been described in a number of cancer specimens The aim of the present study was to investigate the influence of the p53 content of cancer cells on the outcome of the disease. Two monoclonal antibodies (MAbs) recognising epitopes present on the wild-type protein (pAb 421: C-terminal and 1801: N-terminal) and the mutant-specific pAb 240 were used. Immunoreactivity was assayed on nuclear suspensions obtained by dissociation of surgical specimens of colorectal cancer and on the soluble fractions using a two point ELISA.
An increasing body of evidence implicates the cellular antioncogene p53 in the development of human colorectal malignancy. In parallel to the discovery of the recurrent loss of the short arm of chromosome 17 (17p) by cytogenetic analysis (Muleris et al., 1985; , allelic losses were described, with probes specific for the short arm of chromosome 17, as well as for other chromosome segments (Fearon et al., 1987; Law et al., 1988; Delattre et al., 1989; Vogelstein et al., 1989; Fearon et al., 1990) . The deletions on 17p were found to encompass a common region containing the p53 gene ) and mutations have been described in a number of cancer specimens . More recently, it was shown that the transfection of a normal p53 gene in colon carcinoma cells inhibited their growth (Baker et al., 1990) .
Data concerning the expression of the protein have been obtained by immunochemical methods. Thus, a number of different groups have reported detection of p53 immunoreactivity in 42-54% of surgical specimens of colorectal cancer. pAb 421 was the most frequently used anti-p53 monoclonal antibody (Crawford et al., 1984 ; Van den Berg et al., 1989; Remvikos et al., 1990) , but there has been one recent report about immunodetection with pAb 1801 (Purdie et al., 1991) and a small series using pAb 240 (Rodrigues et al., 1990) .
Mutations in the gene have been shown to provoke common conformational changes recognised by specific monoclonal antibodies, defining pAb 246-reactive 'pseudo-wild type' or 'overtly mutant' protein which reacts with pAb 240 ) and human lung carcinomas , confirming its specificity for the altered p53 protein.
The aim of the present study was to investigate the influence of the p53 content of cancer cells on the outcome of the disease. Two monoclonal antibodies (MAbs) recognising epitopes present on the wild-type protein (pAb 421: C-terminal and 1801: N-terminal) and the mutant-specific pAb 240 were used. Immunoreactivity was assayed on nuclear suspensions obtained by dissociation of surgical specimens of colorectal cancer and on the soluble fractions using a two point ELISA.
Materials and methods
The breast cancer cell line MDA-MB231 was cultured in a 1:1 mixture of DMEM and HAM F12 with 10% foetal calf serum (FCS) and 2% glutamine. A-431 cells (squamous carcinoma of the vulva) and HeLa cells (carcinoma of the cervix) were cultured in DMEM with 10% FCS. HL-60, myeloid leukaemia cells were cultured in RPMI 1640 with 20% FCS. In all cases exponentially growing cultures were harvested as previously described (Hammel et al., 1991) and stored in liquid nitrogen.
A-431 and MDA-MB231 cells, which have been shown to contain homozygous p53 mutations Chen et al., 1990) , were used as positive controls, HeLa cells, in which the p53 protein has been reported to be undetectable (Matlashewski et al., 1986) , and HL60 cells that do not contain p53 mRNA consecutive to large deletions in the gene (Wolf & Rotter, 1985) , were used as negative controls. Small tissue fragments were dissociated as previously described (Remvikos et al., 1990) . Nuclear and soluble fractions were separated by a 20 s centrifugation at 10,000g. The nuclear suspensions were stained for FCM analysis, while the supernatants were used in the ELISA. The tumour nuclei were filtered on nylon sheets (50 ytm mesh), washed once with PBS and separated into equal fractions before incubation with the various antibodies. Seventy-three tumours were analysed on a FACSTAR (Becton-Dickinson), equipped with a doublet discrimination 0 module and five were part of the previously published series (Remvikos et al., 1990) . Settings were log for green fluorescence (p53) and linear for red fluorescence (DNA). Graphical representations and statistics were performed with the Consort 30 software. The fluorescence indices, taking into account the difference between total and non-specific fluorescences measured by FCM, were established for every case. The threshold value for positivity was 0.50, as previously described (Remvikos et al., 1990) .
Frozen sections from 16 tumours and paraffin sections from 46 tumours were available for immunohistochemistry. Endogenous peroxidase activity was inhibited by incubation with methanol + H202 (0.5%) for 15 min. Sections were incubated with anti-p53 polyclonal antibody CM1 at a dilution of 1:1000 for 1 h and the staining was revealed using the LSAB kit (DAKO) with diaminobenzidine as the substrate. Haematoxylin was used to counterstain nuclei.
A 2-point ELISA was used to detect p53 in the soluble fractions. The microtitre wells were incubated with anti-p53 polyclonal antibody CM1 at a dilution of 1:1000 for 2 h, and they were rinsed once with PBS-BSA (0.5%). The wells were saturated with PBS-BSA (0.5%) for 1 h, and were rinsed three times with PBS-BSA (0.1%)+ Tween 20 (0.1%). The soluble fractions from tumours were distributed into the wells and incubated overnight at 4°C. After three rinses, the wells were incubated with pAb 240 at a dilution of 1:10 for 2 h at 37°C, and next with peroxidase-conjugated anti-mouse IgGI at a dilution of 1:3000 for 1 h at 37'C. Background levels were established in the absence of sample or with samples incubated with mouse IgGI (Southern) at 1 gLg ml-' instead of pAb 240. 0-phenylenediamine (ABBOTT) was used as the coloured substrate of peroxidase. The staining was stabilised with 4N sulphuric acid and quantified with a TEKAN LP500 at 492 nm. Differences in survival were tested using the log-rank test and actuarial survival curves were plotted according to the Kaplan-Meier method.
Results
An increase in immunofluorescence was observed for some nuclear suspensions from cancer specimens, incubated in the presence of anti-p53 monoclonal antibodies. For the diploid cancer shown in Figure 1 , pAb 421 and 1801 produced similar shifts, while pAb 240 produced a somewhat weaker one. Six cases showed reproducible 1801 and 240 positivity, while the fluorescence histogram for 421 was indistinguishable from that of the isotypic control (Figure 2) . A further seven cases were shown to react only with pAb 240. As for the cancer shown in Figure 3 , the majority of the nuclei in the suspensions of six of the seven cases had hyperdiploid DNA content. The increase in fluorescence for pAb 240 was observed only for the hyperdiploid component. In some cases, the staining patterns presented some heterogeneity. remaining 12 cancers included the five pAb 421 + cases from the previous study and seven cases for which the assay was considered to be non informative, because of insufficient yield of tumour nuclei from the fragments. Although FCM and ELISA results showed a good correlation, a number of different situations were observed. A high content of nuclearattached p53 was demonstrated by FCM for the case shown in Figure 4 , while no p53 was found in the soluble fraction. On the other hand, the case presented in Figure 5 for which FCM analysis showed similar levels of nuclear-attached p53 to the previous case, produced one of the strongest signals in the ELISA. Only two of the 27 ELISA-positive cases were entirely negative on FCM. One of them presented positive nuclei on immunohistochemical analysis (Figure 6 ) and the other one only showed faint cytoplasmic staining (not shown).
The p53 content of the 78 cancers was compared to the other biological parameters (17p loss and DNA content), as well as pathological stage and tumour site (Table 1) . No significant correlation was found with Dukes' stage (P= 0.15), but a highly significant correlation was obtained with DNA index > 1.30 (P<0.0001) as well as 17p loss (P< 0.002). p53 content was also significantly different when it was compared to tumour site (P<0.03), with a considerably reduced incidence in the proximal colon (42.1% positive cases) compared to an average of 74.8% in the distal segments. The median follow-up for the 78 patients was 42 months. Actuarial overall survival curves according to a low or high p53 content are shown in Figure 7 (top panel). A high p53 content was found to be significantly linked to cancer mortality (P<0.03). The analysis was repeated after exclusion of the 14 stage D patients (not shown); in this case the difference did not reach statistical significance (P<0.07). The p53 content (for the non-metastatic patients) was found to be significantly predictive of disease-free ( Since the p53 content was established by two methods, we were able to test its prognostic influence in different subgroups, according to MAb positivity or FCM vs ELISA. As shown in Table II , the most discriminant factor was found to be FCM-defined pAb 240 positivity (nuclear attached p53).
Discussion
In our study, FCM analysis was used as a very sensitive method to investigate the p53 attached to the nuclei of colorectal carcinomas. Also, the use of monoclonal antibodies specific to the C-terminal (pAb 421) (Hammel et al., 1991) . However the effect of the fixation and permeabilisation procedure prior to application of the antibodies cannot be accounted for. We therefore developed a 2-point ELISA in order to quantify p53 in the soluble fractions of the initial dissociation step. The 'revealing' antibody in this case was also the mutated p53-specific pAb 240. (Bartek et al., 1991) , lung cancers and melanomas (Stretch et al., 1991) .
The present study concluded that a high proportion of human colorectal cancers (67%) express increased levels of p53 immunoreactive with the mutated protein-specific monoclonal antibody pAb 240. However, the association with gene mutations has yet to be established. A number of colon or lung cancer cell lines have been described in which p53 protein can behave as mutant, while no evidence of mutations could be obtained (Rodrigues et al., 1990 ; Lehman et al., 1991) . Thus, a better understanding of the properties of the p53 variants in colorectal cancers will be achieved after characterisation of the molecular events at the gene level.
Mutations of the p53 gene have been shown to be related to the loss of one allele of the short arm of chromosome 17 (Baker et al., 1990) . As expected, a similar correlation was found between 17p loss and increased levels of p53 protein displaying a mutation-specific epitope. We also observed a correlation between an increased p53 content and a DNA index > 1.30. It must be stressed that a DNA index > 1.30 has been previously found to be significantly linked with 17p loss (Delattre et al., 1989) . Thus it seems that the three parameters, 17p loss, high p53 protein content and hyperdiploid DNA content are closely interrelated.
In a series of 78 colorectal tumours, with a median followup of 42 months, we have shown that p53 was predictive of disease-free and overall survival. FCM-defined pAb 240 positivity was shown to be the most discriminant in terms of prognosis. This finding could be explained by the fact that recurrences occur in the high p53 group irrespective of the presence of the terminal epitopes. Recently, Scott et al. concluded on the absence of prognostic significance of nuclear p53 (Scott et al., 1991) . In their study, pAb 421 was used to stain p53 on frozen sections. These negative results could be due to the inability to obtain sufficient information concerning the presence of p53 with this particular MAb.
Because the results concerned only a short series of patients, we decided not to perform multivariate analysis. The small number of events in the low p53 group makes the statistical tests relatively unreliable. Nonetheless, the proportion of patients free of disease in the low p53 group was strikingly high (>80%), compared to that in the high p53 group (<50%).
Two different studies have concluded on the independent prognostic significance of 17p loss in colorectal cancers (Kern et al., 1989; Laurent-Puig et al., 1991 Despite the fact that genetic alterations of the p53 gene are probably among the most frequently occurring in human cancers (reviewed in Holstein et al., 1991) , this is the first time that the high content of a protein in the mutant conformation (defined immunologically) was found to influence patient outcome. The characterisation of the mutations might allow us to determine whether these are simply associated with the loss of its antioncogenic function or if the increased expression of the 'mutated' protein is indeed the key event.
In the latter case, it can be hypothesised, at least for colorectal cancers, that p53 mutations can lead a step further from the recessive antioncogene scheme (Levine et al., 1991) , since some mutations might confer 'oncogenic' properties to the protein.
